Melfiat Weight Loss Tablets – Benefits & Side Effects

Introduction to Melfiat

Melfiat is a prescription medication used for weight loss and obesity treatment. It belongs to the morpholine class of drugs and works as an appetite suppressant by stimulating the central nervous system (CNS). Melfiat is typically prescribed as part of a comprehensive weight loss program that includes a reduced-calorie diet, increased physical activity, and behavior change.

armacology”>Ph armacological Profile

Melfiat contains the active ingredient phendimetrazine, which is classified as a CNS stimulant and anorexiant. It increases heart rate and reduces appetite by acting on the nerves and brain. Phendimetrazine is chemically related to amphetamines but has a lower potential for abuse and dependence. Studies have shown that phendimetrazine can lead to significant weight loss when used in combination with lifestyle modifications.

Uses of Melfiat

Melfiat is primarily indicated for the management of obesity and overweight in patients with an initial body mass index (BMI) ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes, hyperlipidemia). It should be used in conjunction with a reduced-calorie diet and increased physical activity for patients who have not responded to diet and exercise alone. Melfiat is typically prescribed for short-term use (a few weeks) as an adjunct to a weight loss program.

Dosage and Administration

Melfiat is available as extended-release capsules in strengths of 105 mg phendimetrazine tartrate. The usual adult dose is one capsule taken once a day, swallowed whole, in the morning or early afternoon. Late evening medication should be avoided due to the potential for insomnia. Dosage should be individualized according to the patient’s response and tolerability. The maximum recommended dose is 105 mg once daily or 70 mg twice daily.

Brands and Generic Names

Melfiat is the brand name for phendimetrazine tartrate extended-release capsules. Other brand names include Bontril, Obezine, Phendiet, Plegine, Prelu-2, and Statobex. Phendimetrazine is the generic name for the active ingredient in Melfiat.

Side Effects and Warnings

Common side effects of Melfiat include dry mouth, constipation, difficulty sleeping, dizziness, restlessness, and irritability. More serious side effects may include chest pain, shortness of breath, fainting, rapid heartbeat, confusion, and severe headache. Melfiat can be habit-forming and should not be used by patients with a history of drug abuse or dependence. It is contraindicated in patients with advanced cardiovascular disease, glaucoma, hyperthyroidism, or a history of allergic reactions to sympathomimetic amines. Warnings and precautions include the risk of abuse and dependence, hypertension, and valvular heart disease.

Mechanism of Action

Melfiat works by stimulating the release of norepinephrine and dopamine in the brain, which leads to increased energy expenditure and decreased appetite. It also inhibits the reuptake of these neurotransmitters, prolonging their effects. The exact mechanism by which Melfiat suppresses appetite is not fully understood, but it is thought to involve activation of the sympathetic nervous system and modulation of hypothalamic appetite-regulating centers.

Clinical Efficacy

Several clinical trials have demonstrated the efficacy of Melfiat for weight loss. In a 12-week, double-blind, placebo-controlled study, patients receiving Melfiat lost an average of 11.8 pounds, compared to 4.9 pounds in the placebo group. Another study found that patients taking Melfiat for 36 weeks lost an average of 17.6 pounds, compared to 7.3 pounds with placebo. The combination of Melfiat with a reduced-calorie diet and exercise program leads to greater weight loss than diet and exercise alone.

Patient Considerations

Melfiat is generally well-tolerated, but some patients may experience side effects that limit its use. It should be used with caution in patients with hypertension, diabetes, or hyperthyroidism. Patients should be monitored for signs of abuse or dependence, and Melfiat should be discontinued if such signs emerge. Pregnant or breastfeeding women should not use Melfiat due to the potential for adverse effects on the fetus or infant. The safety and efficacy of Melfiat in children under 16 years of age have not been established.

Legal and Regulatory Status

Melfiat is a controlled substance (Schedule III) due to its potential for abuse and dependence. It is available only by prescription from a licensed healthcare provider. The Food and Drug Administration (FDA) has approved Melfiat for short-term use (up to 12 weeks) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.